Barings LLC reduced its holdings in Humana Inc (NYSE:HUM) by 13.3% during the 1st quarter, Holdings Channel reports. The institutional investor owned 5,083 shares of the insurance provider’s stock after selling 780 shares during the quarter. Barings LLC’s holdings in Humana were worth $1,352,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the business. We Are One Seven LLC acquired a new position in shares of Humana during the 4th quarter worth about $31,000. Proficio Capital Partners LLC increased its stake in shares of Humana by 81.4% during the 4th quarter. Proficio Capital Partners LLC now owns 107 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 48 shares during the last quarter. Destination Wealth Management increased its stake in shares of Humana by 130.0% during the 1st quarter. Destination Wealth Management now owns 115 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 65 shares during the last quarter. Exane Asset Management acquired a new position in shares of Humana during the 4th quarter worth about $43,000. Finally, Sontag Advisory LLC acquired a new position in shares of Humana during the 4th quarter worth about $47,000. Hedge funds and other institutional investors own 92.64% of the company’s stock.
HUM has been the topic of several recent analyst reports. SunTrust Banks lowered their price objective on shares of Humana to $300.00 in a research note on Thursday, May 2nd. Citigroup lowered their price objective on shares of Humana from $397.00 to $362.00 and set a “buy” rating on the stock in a research note on Thursday, February 7th. Morgan Stanley set a $331.00 price objective on shares of Humana and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Finally, UBS Group initiated coverage on shares of Humana in a research note on Tuesday, April 23rd. They set a “neutral” rating and a $266.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company. Humana presently has an average rating of “Buy” and a consensus target price of $337.26.
Shares of HUM stock opened at $263.33 on Monday. The stock has a market cap of $35.56 billion, a P/E ratio of 16.81, a P/E/G ratio of 1.08 and a beta of 0.88. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.40. Humana Inc has a 52 week low of $225.65 and a 52 week high of $355.88.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, topping the consensus estimate of $4.30 by $0.18. The business had revenue of $16.11 billion during the quarter, compared to the consensus estimate of $15.67 billion. Humana had a net margin of 2.99% and a return on equity of 20.77%. Humana’s revenue was up 12.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.36 EPS. On average, research analysts forecast that Humana Inc will post 17.57 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.84%. The ex-dividend date of this dividend is Thursday, June 27th. Humana’s payout ratio is 15.12%.
WARNING: This report was first published by Zolmax and is owned by of Zolmax. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://zolmax.com/investing/barings-llc-sells-780-shares-of-humana-inc-hum/3096606.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Article: Why is the price-sales ratio important?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.